SP600125 Liposomes, Formulation HZ12

DLL-0018-A1-10ML

SP600125 Liposomes, Formulation HZ12

PEGylated liposomes containing JNK inhibitor SP600125 (Nsc75890). SP600125 is a reversible, ATP-competitive broad-spectrum JNK inhibitor (JNK1/JNK2, IC50 40 nM; JNK3, IC50 90 nM). with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is also a broad‐spectrum inhibitor of serine/threonine kinases including Aurora kinase A，FLT3 and TRKA. SP600125 inhibits ferroptosis, autophagy, and activates apoptosis. SP600125 is insoluble in aqueous media. This product is a pre-formulated liposomal version of Sp600125 which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

2995 €

27023

SP600125

Novel, potent and selective JNK-1,-2, and -3 inhibitor (Ki = 0.19 µM). SP600125 is an ATP-competitive reversible inhibitor with >20-fold selectivity vs. a range of kinases and enzymes tested. In cells, SP600125 caused a dose-dependent inhibition of the phosphorylation of c-Jun, the expression of inflammatory genes IL-2, COX-2, TNF-α, IFN-γ, and blocked the activation and differentiation of primary human CD4 cell cultures.

345 €

1669-5

SP600125

405.6 €

MBS6008609-02mL

SP140L, ID (SP140L, Nuclear body protein SP140-like protein)

1071.12 €

MBS6008609-5x02mL

SP140L, ID (SP140L, Nuclear body protein SP140-like protein)

3978.12 €

MBS6350163-02mL

SP140L, ID (SP140L, Nuclear body protein SP140-like protein) (APC)

1434.5 €